MED - NYSE
Medifast, Inc.
$12.27
-0.37%Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. The company offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serves, shakes, smoothies, soft bakes, and soups under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. It markets its products through point-of-sale transactions over ecommerce platform. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
At a Glance
Live SnapshotMedifast, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
CapEx Intensity
Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Medifast, Inc. Cash Flow Statement
MED • NYSE
| Medifast, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
-18.7M | 2.1M | 99.4M | 143.6M | 164M | 102.9M | 77.9M | 55.8M | 27.7M | 17.8M | 19.6M | 21M | 24M | 15.9M | 18.5M | 19.6M | 12M | 5.4M | 3.8M | 5.1M | |
14.2M | 17.4M | 13.1M | 11M | 6.8M | 4.3M | 4.6M | 4.4M | 4.2M | 5.4M | 7.1M | 8.1M | 11.4M | 11.2M | 8.3M | 5.9M | 5.3M | 4.6M | 3.5M | 2.4M | |
11.5M | -7.4M | 1.2M | -924K | -3.7M | 601K | 1.6M | -2.7M | -623K | -2.8M | -106K | 286K | -888K | -1.3M | 6M | -70K | 0.0 | -234K | -390K | -648K | |
7.6M | 7.4M | 8.2M | 11.1M | 9.9M | 6.8M | 4.5M | 3.1M | 4.3M | 3.4M | 3.1M | 3.9M | 3.2M | 2.9M | 2.5M | 2.7M | 0.0 | 852K | 0.0 | 0.0 | |
2M | 14.8M | 5.5M | 8.2M | 5.2M | 3.7M | 4.1M | 622K | 879K | 5.7M | -4.1M | -2.6M | 351K | 119K | 207K | 205K | 2.9M | -350K | 811K | 703K | |
(0.0) | (0.0) | (34.3M) | (37.2M) | (56.8M) | (24.6M) | (17.3M) | (14.6M) | (13.6M) | (11.6M) | (4.2M) | (12.7M) | (10M) | (4.1M) | (4.1M) | (10.7M) | (9.2M) | (3.7M) | (0.0) | (0.0) | |
-9.8M | -9.7M | 20.3M | 21.7M | -87.6M | 26.9M | -8.5M | -467K | 6.8M | -4.2M | 3.8M | -5.1M | 4.3M | 11.6M | -761K | 486K | 150K | -4.8M | 135K | -1.9M | |
6.9M | 24.5M | 147.7M | 194.6M | 94.5M | 145.2M | 84.3M | 60.8M | 43.2M | 25.4M | 29.4M | 25.5M | 42.4M | 40.3M | 34.9M | 28.8M | 20.3M | 5.5M | 8M | 5.8M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-5.6M | -7.5M | -6.5M | -16.7M | -34.2M | -5.9M | -10.1M | -4.9M | -3.2M | -2.9M | -2.8M | -7M | -11.6M | -11.4M | -14.7M | -12.1M | -5.4M | -7.4M | -8M | -8M | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (196K) | (81K) | (676K) | (0.0) | (0.0) | (0.0) | (0.0) | (387K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-84.4M | -46.6M | -54.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -7M | -26.6M | -9.3M | -26.1M | -25.4M | -8.4M | -10.3M | -17M | -2.6M | (0.0) | -4K | (0.0) | |
78.8M | 27.4M | 0.0 | 5.3M | 5.1M | 4.6M | 3.7M | 3.5M | 7M | 26.7M | 11.9M | 29.6M | 14.4M | 8.1M | 8.1M | 5.5M | 0.0 | 129K | 0.0 | 1.2M | |
3.3M | 95K | 0.0 | 0.0 | 0.0 | 0.0 | 3.7M | 196K | 81K | 676K | 2.6M | 950K | -11.2M | -3.5M | -387K | 0.0 | 0.0 | -13K | 0.0 | 0.0 | |
-7.9M | -26.5M | -61M | -11.4M | -29.1M | -1.3M | -6.3M | -1.2M | -3.2M | -2M | -189K | -2.5M | -22.6M | -11.7M | -16.9M | -23.5M | -7.9M | -7.3M | -8M | -6.7M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-369K | -836K | -7M | -128M | -62.1M | -5.6M | -47.2M | -30.7M | -2.5M | -1.3M | -11.8M | -35M | -20.1M | -2.8M | -20.4M | -35K | 112K | 30K | -93K | 375K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -219K | -255K | -222K | -3.6M | -1.4M | -1.1M | -436K | -1.3M | 1.4M | 1.3M | 142K | |
-195K | -715K | -73M | -71.6M | -63.9M | -53.2M | -35.4M | -23.2M | -15.4M | -11.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-369K | -836K | -7M | -128M | -62.1M | -5.6M | -47.2M | -30.7M | -2.5M | -1.3M | -11.8M | -35M | -20.1M | -2.8M | -20.4M | -35K | -102K | (0.0) | -309K | -420K | |
0.0 | 36K | 188K | 0.0 | 811K | 1.6M | 278K | 547K | 568K | 529K | 336K | 327K | 409K | 1.3M | 626K | 1.8M | -303K | 0.0 | -39K | -14K | |
-564K | -1.5M | -79.8M | -199.6M | -125.1M | -57.1M | -82.3M | -53.3M | -17.4M | -12.9M | -11.7M | -34.9M | -23.3M | -2.9M | -20.9M | 1.3M | -1.5M | 1.5M | 1.1M | 503K | |
CASH FLOW SUMMARY | ||||||||||||||||||||
4K | 47K | -72K | -67K | 112K | -21K | 1K | -2K | -71K | 7K | 87K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.6M | -3.5M | 6.7M | -16.5M | -59.5M | 86.7M | -4.4M | 6.3M | 22.6M | 10.4M | 17.6M | -11.9M | -3.6M | 25.7M | -2.9M | 6.6M | 10.9M | -354K | 1.1M | -399K | |
90.9M | 94.4M | 87.7M | 104.2M | 163.7M | 77M | 81.4M | 75.1M | 52.4M | 42M | 24.5M | 36.4M | 39.9M | 14.3M | 17.2M | 10.6M | 1.8M | 2.2M | 1.1M | 1.5M | |
89.3M | 90.9M | 94.4M | 87.7M | 104.2M | 163.7M | 77M | 81.4M | 75.1M | 52.4M | 42M | 24.5M | 36.4M | 39.9M | 14.3M | 17.2M | 12.7M | 1.8M | 2.2M | 1.1M | |
1.2M | 17M | 141.2M | 177.9M | 60.3M | 139.3M | 74.2M | 55.9M | 40M | 22.5M | 26.6M | 18.5M | 30.8M | 28.9M | 20.2M | 16.7M | 15M | -1.9M | -11K | -2.1M |
SEC Filings
MED - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 01, 2026 | May 29, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 26, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | May 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2025 N/A | January 05, 2026 | December 30, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your MED research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.